Abstract Details

Title Effect of Radicava on Uric Acid Levels: Preliminary Results

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P4 - Poster Session 4 (5:30 PM-6:30 PM)

Poster/Presentation
Number 12-034

Objective To assess the effects of Radicava on serum uric acid (UA) levels in ALS

Background Radicava, recently approved for treatment of Amyotrophic Lateral Sclerosi (ALS), likely works as a free radical scavenger to reduce oxidative stress. Previous studies in ALS have demonstrated that UA, an endogenous antioxidant, may play a protective role by scavenging oxygen free radicals and reducing oxidative stress. Decreased levels of UA are reported in ALS compared to controls and increased urate levels are associated with reduced risk of all-cause mortality in ALS. A small study suggested that treatment with Radicava may increase UA levels suggesting that Radicava effects may be, at least in part, mediated by UA-modulated mechanisms.

Design/Methods Serum UA levels were measured before and after each cycle of Radicava over successive treatment cycles. Pre and Post-treatment levels were compared using a paired t-test. Additionally the effect over time was examined in each individual to see if any incremental changes in UA levels occurred over time. The influence of gender and site of onset on UA levels with Radicava was also examined.

Results There were 18 subjects (3F,15M) with average age of onset 56y(27–75y). Onset was bulbar in 3 and limb in 15 subjects. Duration of disease averaged 54 months (9-156) at the time of treatment. Subjects had from 1-12 cycles of treatment. There was no significant difference between pre and post-Radicava treatment in UA levels(4.5+/-1.21vs .35 +/-1.27,p=.059) for each cycle as well as between the first pre-treatment and the final level following up to 12 treatment cycles, nor between pre and post UA in males(4.81+/-1.0vs4.67+/-1.18,p=0.09), females(3.57+/-1.1vs3.613+/-1.38,p=0.78), limb-onset(4.78+/-0.96vs4.69+/-1.14;p=0.2) and bulbar onset (3.54 +/- 0.99vs3.16 +/- 0.86,p=0.01).

Conclusions There was no significant change in serum UA levels over the course of Radicava treatment in this small cohort of subjects. Studies should continue with a more subjects.

Authors/Disclosures
Terry D. Heiman-Patterson, MD (Temple University Lewis Katz School of Medicine) PRESENTER	Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MTPA. Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Heiman-Patterson has received personal compensation in the range of $0-$499 for serving as a Consultant for novartis. Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for biogen. The institution of Dr. Heiman-Patterson has received research support from MTPA. The institution of Dr. Heiman-Patterson has received research support from State of Pennsylvania . The institution of Dr. Heiman-Patterson has received research support from ALS Association. The institution of Dr. Heiman-Patterson has received research support from ALS United. The institution of Dr. Heiman-Patterson has received research support from ALS Hope Foundation.
John Furey (Temple University Hospital)	Mr. Furey has nothing to disclose.
	No disclosure on file
Anahita F. Deboo, MD (Temple University School of Medicine - Neurology)	Dr. Deboo has nothing to disclose.
Justin Y. Kwan, MD, FAAN (National Institutes of Health)	Dr. Kwan has received research support from National Institutes of Health. Dr. Kwan has received personal compensation in the range of $100,000-$499,999 for serving as a Employee with National Institutes of Health.
Sabrina Paganoni, MD, PhD	Dr. Paganoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cytokinetics. Dr. Paganoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jannsen. Dr. Paganoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arrowhead. Dr. Paganoni has received personal compensation in the range of $0-$499 for serving as a Consultant for Sola. Dr. Paganoni has received personal compensation in the range of $0-$499 for serving as a Consultant for Frequency Therapeutics. The institution of Dr. Paganoni has received research support from Amylyx. The institution of Dr. Paganoni has received research support from Revalesio. The institution of Dr. Paganoni has received research support from Alector. The institution of Dr. Paganoni has received research support from UCB. The institution of Dr. Paganoni has received research support from Biohaven. The institution of Dr. Paganoni has received research support from Clene. The institution of Dr. Paganoni has received research support from Prilenia. The institution of Dr. Paganoni has received research support from Seelos. The institution of Dr. Paganoni has received research support from Calico. The institution of Dr. Paganoni has received research support from Denali. The institution of Dr. Paganoni has received research support from Anelixis. The institution of Dr. Paganoni has received research support from Cytokinetics.

��ɫ��

��ɫ��